Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18161742 | 0.85 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL14692513 | 0.83 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL14692634 | 0.80 | PTGS1 (0.54) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL30879827 | 0.79 | PTGS2 (0.54) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL30879822 | 0.78 | CDC7 (0.38) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL30879823 | 0.72 | PTGS1 (0.35) | MAPK14PTGS1PTGS2 | |
| SCHEMBL30879808 | 0.72 | HIPK4 (0.45) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL4462830 | 0.72 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11GSK3B | |
| SCHEMBL20376630 | 0.70 | KDM4E (0.47) | MAPK14MAPK13MAPK12MAPK11PTGS1 | |
| SCHEMBL20376337 | 0.69 | PTGS2 (0.58) | MAPK14MAPK11PTGS1PTGS2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139194-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2024-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139194-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | MAPK14 113/4885MAPK13 199/4885MAPK12 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.